about
Drug interactions and antiretroviral drug monitoring.Biochemical interaction of anti-HCV telaprevir with the ABC transporters P-glycoprotein and breast cancer resistance proteinPopulation pharmacokinetic modeling of plasma and intracellular ribavirin concentrations in patients with chronic hepatitis C virus infectionEvaluation of the Pharmacokinetics and Renal Excretion of Simeprevir in Subjects with Renal ImpairmentPharmacokinetic interaction between telaprevir and methadoneMultiplex liquid chromatography-tandem mass spectrometry assay for simultaneous therapeutic drug monitoring of ribavirin, boceprevir, and telaprevir.Telaprevir: clinical pharmacokinetics, pharmacodynamics, and drug-drug interactions.Optimizing the in vitro and clinical assessment of drug interaction risk by understanding co-medications in patient populations.Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerations.Drug interactions and protease inhibitors used in the treatment of hepatitis C: how to manage?New therapies for hepatitis C: considerations in patients with renal impairment.Variations of pharmacokinetics of drugs in patients with cirrhosis.A strategy for early-risk predictions of clinical drug-drug interactions involving the GastroPlusTM DDI module for time-dependent CYP inhibitors.Pharmacokinetic interaction between etravirine or rilpivirine and telaprevir in healthy volunteers: A randomized, two-way crossover trial.A pharmacokinetic-viral kinetic model describes the effect of alisporivir as monotherapy or in combination with peg-IFN on hepatitis C virologic response.Determination of telaprevir in plasma of HCV-infected patients by HPLC-UV.Clinical risks of St John's Wort (Hypericum perforatum) co-administration.Treatment of chronic hepatitis C with protease inhibitor-based therapy after liver transplantation.Pharmacokinetic characteristics of telaprevir in healthy Korean male subjects and comparisons with Japanese.
P2860
Q34021173-31FF144A-CBBB-4889-84ED-07BEAF671DBDQ35033091-BE07DF0A-42A2-4124-BAA3-DA63E6406EB2Q35169059-0975582C-9339-4727-9A06-68110F0AE99AQ36031127-32AB59B4-F331-482F-B000-A745090C3C44Q36785929-47D11495-3D05-4323-8865-005F118D1C11Q36969893-BCCD7000-96BD-44B4-BE82-9904364434BCQ38095820-C5D54CA5-9CFB-4F22-ADF0-D521D6FA0DE4Q38099049-67218446-338B-485E-AC37-D98AC2A196DBQ38203823-8707AB8A-AE52-4D33-968B-F15A9179B340Q38210969-1FD07070-9EC3-4960-8477-2F95C2BC58A4Q38233834-9359FE81-68CA-4E06-8EF2-A129FBD6C258Q38676890-EE2821BC-ABEE-4D8A-97E2-86D00EACD3D2Q38819541-A5EBB842-63D4-4680-8DEB-EF20031AD2D2Q41230514-F1214480-020D-4961-9CFF-6D48A0B3CA24Q42196934-5C75F263-F724-40AA-92FE-3B4E432B2623Q42280851-EAF0B117-A9AC-4B22-B2E2-5A57204E812CQ47774682-03C090F8-22EE-4092-BD0F-4811B1A9BC78Q47878009-43E80684-0F2A-424B-905B-AC8376A78FEEQ55164145-981CEFA3-0CAB-411D-B54A-EF9CB4D9B9AD
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Telaprevir: pharmacokinetics and drug interactions.
@en
type
label
Telaprevir: pharmacokinetics and drug interactions.
@en
prefLabel
Telaprevir: pharmacokinetics and drug interactions.
@en
P2093
P356
P1433
P1476
Telaprevir: pharmacokinetics and drug interactions.
@en
P2093
Maria Beaumont
Robert S Kauffman
Rolf P G van Heeswijk
Varun Garg
P304
P356
10.3851/IMP2356
P577
2012-09-07T00:00:00Z